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Hypertension and Congestive Heart Failure: Benefits of Converting
Enzyme Inhibition (Captopril)
HARALAMBOSGAVRAS,MD
Boston. Massachusetts
Congestive heart failure is a frequent complication of
hypertension. This is a brief review of the mechanisms
precipitating heart failure, as well as the various ap-
proaches to t;eatment of this complication. Emphasis is
given to the rationale for treating congestiveheart failure
Of all the potential complications of hypertension, conges-
tive heart failure was most consistently found to be pre-
ventable or reversible by good blood pressure control. Un-
like coronary artery disease and thrombotic stroke, which
have a strong statistical association but a less clear causal
relation with high blood pressure, the pathophysiology of
heart failure is clearly related to the level of blood pressure.
Systolic pressure is the main determinant of impedance to
left ventricular outflow-the so-called afterload-as well
as of the left ventricular work necessary to overcome the
impedance. This relation can be expressed as: CW = SV
X HR x SBP, where CW = cardiac work, SV = stroke
volume, HR = heart rate and SBP = mean blood pressure
during systole (I). Inability of the heart to perform this work
results in pump failure.
Approaches to Treatment of Heart Failure
Traditionally, treatment for congestive heart failure con-
sists of administration of diuretic and inotropic agents. Di-
uretic agents decrease the left ventricular filling pressure or
"preload" by removing excessive fluid volume and causing
some degree of venous pooling. Although these drugs re-
lieve congestion, they tend to decrease further the already
diminished cardiac output.
Agents with a positive inotropic action, such as digitalis
and sympathomimetic amines, stimulate myocardial con-
From the Department of Medicine, Boston City Hospital and Boston
University School of Medicine. Boston, Massachusetts. This study was
supported in part by Grant HL-18318 from the U. S. Public Health Service,
Bethesda, Maryland.
Address for reprints: Haralambos Gavras, MD, 80 East Concord Street,
Boston. Massachusetts 02118.
© 1983 by the American College of Cardiology
with vasodilation and by chronic angiotensin-converting
enzyme inhibition with captopril. A summary is pre-
sented of clinical experience with this agent over the past
few years together with an outline of the characteristics
that make it different from pharmacologic vasodilators.
tractility and help the cardiac pump to increase its output
and overcome the high impedance (provided that the heart
is capable of responding to such stimulation), which in turn
further increases cardiac work and myocardial oxygen con-
sumption. If the heart is unable to respond because of car-
diomyopathy or if the coronary circulation cannot satisfy
the increased oxygen demand, inotropic agents are of little
help.
A third approach to the treatment of congestive heart
failure is reduction of the afterload by the use of vasodila-
tors (2). A variety of drugs have been used for this purpose.
Some act only on the arterial side of the circulation, that
is, the resistance vessels (hydralazine and minoxidil. for
example), whereas others also act on the venous side, thus
diminishing both the preload and afterload (sodium nitro-
prusside and prazosin, for example). The rationale for their
use is that congestive heart failure is characterized by greatly
elevated peripheral vascular resistance, attributed to stim-
ulation of the sympathetic nervous and renin-angiotensin
systems and to stiffness of the vascular wall possibly due
to "waterlogging" from sodium and fluid retention (3,4).
One risk of the use of pharmacologic vasodilators under
these circumstances is the possibility of impaired perfusion
of vital organs from excessive vasodepression.
The Ideal Vasodilator
Reduction of blood pressure per se is helpful to cardiac
economy, but most sympatholytic antihypertensive drugs
tend to attenuate myocardial contractility to various degrees.
In addition, all sympatholytic and vasodilator drugs enhance
the retention of sodium and fluid. Recently Zelis and Flaim (5)
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listed what they consider the characteristics of the ideal
vasodilator. It should:
I. Reduce left ventricular filling pressure, so that the patient
can sleep comfortably without congestive symptoms.
2. Improve renal and splanchnic blood flow, especially dur-
ing exercise. This improved perfusion should lead to
improved renal function and a deactivation of the renin-
angiotensin-aldosterone system.
3. Fail to increase blood flow to any organ above the level
necessary for normal organ function. Thus it would fail
to increase skeletal muscle and cutaneous blood flow
under basal conditions, and especially fail to induce
"shunting" of blood flow across exercising skeletal
muscle.
4. Improve nutritional blood flow to exercising skeletal muscle
modestly, so as to reduce activation of the sympathetic
nervous system.
5. Cause minimal adverse alterations to the number and
affinity of receptors in autonomic nerves and blood ves-
sels, so as to minimize the development of drug tolerance
during long-term use.
Experience With Captopril
Although no such ideal drug is yet available, we believe
that its closest counterpart is angiotensin blockade by con-
verting enzyme inhibition (6-10). We first advocated this
approach 5 years ago with the tentative use of the an-
giotensin antagonist saralasin (11) and the intravenous con-
verting enzyme inhibitor teprotide (12). With the advent of
the orally active converting enzyme inhibitor captopril, this
treatment has gained acceptance as a practical alternative
with several advantages over the pharmacologic vasodilators.
Our own experience to date is derived from 36 patients
treated with captopril for periods varying between a few
weeks to more than 2 years. Patients were followed up for
an average of 18 months, and it appears that the original
response as assessed at 6 to 8 weeks was generally predictive
of the patient's status at 18 months. On average, during this
treatment systemic vascular resistance declined by 30%,
arterial pressure decreased substantially in hypertensive pa-
tients but in normotensive subjects after an initial depression
tended to return toward the baseline. Cardiac index in-
creased by 25 to 40%, pulmonary wedge pressure decreased
by 35 to 48% and left ventricular pressure and right atrial
pressure decreased by 25 and 40%, respectively.
Thus captopril produces hemodynamic changes similar
to those of other vasodilators. Despite the considerable re-
duction of systemic blood pressure, adequate perfusion of
vital organs is maintained because the elimination of an-
giotensin II leads to redistribution of regional blood flows
according to the pattern of sensitivity of each organ's vas-
culature to angiotensin. In the experimental animal, sensi-
tive vessels such as renal, cerebral and, possibly, coronary
arteries receive a larger fraction of the augmented cardiac
output at the expense of the relatively less sensitive mus-
culocutaneous tissues (13). This effect has also been dem-
onstrated to some extent in patients with congestive heart
failure (14,15) and in hypertensive patients (16) whose renal
blood flow and glomerular filtration rate improved during
treatment with a converting enzyme inhibitor. In our series
we found that during converting enzyme inhibition, renal
blood flow increased by 60% and urinary sodium excretion
doubled. In contrast, hepatic blood flow decreased by 17%
and blood flow to the calf muscles remained unchanged.
These findings suggest that cardiac and circulatory function
improves through selective dilation of certain vascular trees
as well as through improvement of renal excretory capacity.
Activation of the renin-angiotensin-aldosterone system is
one of the mechanisms that attenuate the beneficial effects
ofboth vasodilators and diuretic drugs. It leads to peripheral
vasoconstriction and maintenance of elevated systemic re-
sistance. Furthermore, secondary hyperaldosteronism en-
hances retention of sodium and fluid, and thus promotes
vascular wall stiffness and compression of small vessels by
interstitial edema. Chronic inhibition of angiotensin for-
mation interrupts this vicious circle of reactive hyperreninemia.
Another mechanism that limits the hemodynamic benefits
of most vasodilators is stimulation of the sympathetic ner-
vous system activity. Although the resulting positive ino-
tropic effect may be beneficial, the increase in stroke vol-
ume, heart rate and systemic vascular resistance causes a
substantial augmentation of cardiac work that might be un-
desirable in the presence of coronary insufficiency or car-
diomyopathy. Converting enzyme inhibitors actually de-
crease elevated heart rate and peripheral resistance and,
despite the resultant increase in stroke volume and cardiac
output, they ultimately cause cardiac work to diminish. In-
terestingly, it appears that during long-term treatment with
a converting enzyme inhibitor, the vascular reactivity to
norepinephrine tends to decline (17). One possible expla-
nation for this may be that angiotensin II exerts a permissive
effect that enhances the action of catecholamines.
Long-term maintenance therapy: follow-up. Long-term
captopril therapy in patients with severe heart failure re-
fractory to other medications has been demonstrated to offer
these advantages (6-10,14.15). There was no "escape"
from control in follow-up for more than 2 years, as shown
by the sustained improvement in functional capacity and
exercise tolerance. In fact, most patients gained at least one,
but usually two steps in New York Heart Association func-
tional classification. Therapy rarely had to be discontinued
because of side effects such as orthostatic intolerance or
prerenal azotemia; in fact, quite low blood pressures were
surprisingly well tolerated by these patients. Furthermore.
very few of the drug's idiosyncratic reactions have been
reported in such patients. possibly because the dosage needed
for this indication IS considerably lower than that needed
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for blood pressure control in hypertensive patients without
congestive heart failure. However, despite the significant
amelioration in quality of life from relief of symptoms, it
is not clear whether life expectancy is improved. It appears
that the overall mortality rate of these patients with very
severe congestive heart failure remains high because of sud-
den death, coronary events or a gradual decline in the pa-
tient's general health.
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